Abstract:
Objective:To investigate the therapeutic effects of nucleoside analogues (acid) and transarterial chemoembolization (TACE) on hepatitis B- related primary liver cancer. Methods:Cases from Guangzhou Eighth People's Hospital were retrospectively analyzed between January2011and December2015. A total of 174 patients were diagnosed with hepatitis B-related primary liver cancer. Pa-tients were categorized based on needs and individual goals. The control group included patients who were classified based on needs (n=72), whereas the research group included patients who were classified based on individual goals (n=102 ). In the control group, 72 patients underwent TACE. In the research group, 102 patients received nucleoside analogue (acid) and TACE. Results:The two groups did not differ significantly in terms of basic clinical parameters, such as age, sex, tumor size, and laboratory examination (P>0. 05). After treatment, the research group was compared with the control group. The liver function of patients in the research group significantly improved ( P<0. 05). AFP and CA 199 levels significantly decreased after 12, 24, and 48weeks of treatment in the research group (P<0. 05). The research group had HBVDNA unpredictable rates of 13. 73% ,33. 33% ,50. 0% , and 76. 47% after 4, 12, 24, and 48weeks of treatment, respectively. The control group had HBVDNA unpredictable rates of 11. 11%, 16. 67%, 22. 22%, and 25. 00% after 12, 24, and 48weeks of treatment, respectively. The HBVDNA unpredictable rate was significantly higher in the control group ( P<0. 05). The treat -ment effects in theresearch group were better than that of the control group (P<0. 05). In the research group, the 1- and 3-year surviv -al rates were 96. 08% and 90. 20%, respectively. In the control group, the 1- and 3-year survival rates were83. 33% and 63. 89%, respec -tively. The difference in survival rates between the two groups was statistically significant ( P<0. 05). Conclusion: TACE based on com-bined nucleoside analogue (acid) and antiviral treatment improved ALT levels in patients with hepatitis B-related primary liver cancer and decreased AFP, CA199 , and HBVDNA levels. Moreover, the HBVDNA unpredictable rate was modified to facilitate the TACE proce -dure, therefore improving the survival rates of patients and prolonging survival. Therefore, the therapeutic actions of antiviral treatment on hepatitis B-related primary liver cancer should be further investigated.